Systematic review reveals recent market approvals and pipeline candidates between 2013 and 2018, highlighting prodrug strategies to overcome drug delivery drawbacks.
BACKGROUND: The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been reached the drugs market throughout history and the recent years have witnessed a significant increase in the use of prodrugs as a replacement of their parent drugs for an efficient treatment of various ailment. METHODS: A Scan conducted to find recent approved prodrugs and prodrugs in development. RESULTS: Selected prodrugs were reported and categorized in accordance to their target systems. CONCLUSIONS: the prodrug approach has shown many successes and still remains a viable and effective approach to deliver new active agents. This conclusion is supported by the recent approved prodrugs and the scan of clinical trials conducted between 2013-2018.
No takes yet. Share an insight, caveat, or question.
Najjar et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: